Key Clinical Summary: Recognizing High-Risk Patients & Stratifying ASCVD Risk

This is a micro-learning module summary of a presentation by William Callahan, DO which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This program is supported through an independent educational grant from MSD. It is intended for healthcare professionals globally.

Introduction

ASCVD is the leading cause of death worldwide, accounting for approximately one third of all global mortality. Clinically, this corresponds to roughly 16% of deaths from ischaemic heart disease and around 12% from stroke. These are conditions encountered routinely in clinical practice, and importantly, many events are preventable.

Cholesterol physiology

Cholesterol enters circulation from two main sources: endogenous synthesis in the liver (via HMG-CoA reductase) and dietary intake. Following fat ingestion, triglycerides are packaged into chylomicrons, delivered to peripheral tissues, and returned to the liver as remnants.

The liver repackages lipids into very low-density lipoproteins (VLDL), which progressively lose triglyceride content and become intermediate-density lipoproteins (IDL) and ultimately low-density lipoproteins (LDL). LDL particles deliver cholesterol to peripheral tissues. High-density lipoprotein (HDL) mediates reverse cholesterol transport, removing excess cholesterol from tissues and returning it to the liver.

Cholesterol itself is essential for normal cellular function. Pathology arises when circulating LDL particles are present in excess.

ApoB and atherogenic particle burden

Each atherogenic lipoprotein particle, including VLDL, IDL, and LDL, contains one molecule of apolipoprotein B (ApoB). ApoB therefore reflects the number of circulating atherogenic particles. An increased ApoB concentration indicates a higher particle burden and a greater probability of particle retention within the arterial wall, contributing to atherosclerotic plaque development.

Lipoprotein(a) as a risk modifier

Lipoprotein(a) is a genetically determined LDL-like particle that independently increases ASCVD risk and is minimally influenced by lifestyle factors. When available, measurement of lipoprotein(a) can refine risk stratification and should be incorporated into patient discussions as part of a comprehensive assessment of lifetime cardiovascular risk.

Pathophysiology of atherosclerosis

When LDL is present in excess, it circulates in the bloodstream and can become trapped within blood vessel walls. The immune system recognises that LDL should not be present in this location, prompting macrophages to engulf the cholesterol. As macrophages accumulate lipid, they become foam cells, which form the basis of atherosclerotic plaque.

Plaque accumulation is not uniform throughout the vasculature; some vessels develop more plaque than others. Clinical events occur when plaque becomes disrupted, triggering clot formation as the body attempts to repair the injury. This process can obstruct blood flow and lead to ischaemia.

Atherosclerosis develops gradually and is often asymptomatic for many years before clinical events occur.

Atherosclerosis is caused by the progressive trapping og cholesterol-carrying LDL and other apolipoprotein B (APOB)-containing lipoproteins within the arterial wall. As more LDL particles become trapped within the same artery wall over time, the size of the resulting atherosclerotic plaque burden grows and the risk of having an ASCVD event increases.

Cumulative LDL exposure

Atherosclerosis is driven not by a single LDL measurement, but by LDL exposure over time. Sustained elevations in LDL increase the cumulative burden of retained particles within the arterial wall.

Lowering LDL earlier and maintaining lower levels over time reduces the number of LDL particles entering the arterial wall, slows plaque progression, and lowers absolute lifetime ASCVD risk. A reduction of approximately 38–40 mg/dL in LDL cholesterol is associated with an approximate 22% reduction in major adverse cardiovascular events.

Clinical scenario

A 45-year-old man presents for routine assessment with an LDL cholesterol level of 165 mg/dL and a family history of premature myocardial infarction. He has not had regular lipid monitoring in adulthood.

The key clinical implication is not the single LDL value alone, but the likelihood of prolonged exposure to elevated LDL over many years, resulting in cumulative plaque burden and increased ASCVD risk.

Evidence supporting cumulative exposure

Population imaging and longitudinal cohort studies consistently demonstrate the impact of long-term LDL exposure.

In the Swedish Cardiopulmonary Bioimage Study (SCAPIS), among adults aged 50–64 years with no known coronary artery disease, 42.1% had detectable coronary plaque, and 5.2% had stenosis greater than 50%. This burden reflects lipid exposure beginning earlier in life.

The Framingham Heart Study demonstrated that individuals with sustained exposure to high LDL cholesterol had approximately fivefold higher cardiovascular disease risk and fourfold higher all-cause mortality compared with those with optimal LDL levels.

The CARDIA study showed that in younger patients (adults aged 18–30 years) without known heart disease, higher LDL levels and longer duration of exposure were associated with ASCVD events decades later.

Familial hypercholesterolaemia provides further confirmation of the time-dependent nature of LDL exposure. Genetically elevated LDL from birth leads to markedly increased early coronary artery disease risk when untreated.

Clinical implications

Primary prevention is critical. Atherosclerosis develops long before symptoms occur, and delaying intervention forfeits years of potential risk reduction.

Counselling should emphasise that although prior LDL exposure cannot be reversed, reducing LDL now lowers future cumulative exposure and meaningfully reduces lifetime ASCVD risk. Shared decision-making should focus on long-term risk reduction rather than isolated lipid values.

Key messages

ASCVD risk is driven by cumulative exposure to atherogenic LDL particles. ApoB reflects particle number and associated risk. Atherosclerosis begins early and progresses silently. Early and sustained LDL reduction is the most effective strategy for long-term prevention.

Content is accurate as of the date of release.